Haematologica, Vol 92, Issue 1, 50-55 doi:10.3324/haematol.10554
Copyright © 2007 by Ferrata Storti Foundation

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zamagni, E. Articles by Cavo, M. Search for Related Content PubMed PubMed Citation Articles by Zamagni, E. Articles by Cavo, M.

Multiple Myeloma

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma

Elena Zamagni, Cristina Nanni, Francesca Patriarca, Emanuela Englaro, Paolo Castellucci, Onelio Geatti, Patrizia Tosi, Paola Tacchetti, Delia Cangini, Giulia Perrone, Michela Ceccolini, Annamaria Brioli, Silvia Buttignol, Renato Fanin, Eugenio Salizzoni, Michele Baccarani, Stefano Fanti, Michele Cavo

From the Istituto di Ematologia e Oncologia Medica "L. e A. Seràgnoli", Università di Bologna, Italia (EZ, PTo, PTa, DC, GP, MC, AB, MB, MC); Istituto di Medicina Nucleare, Policlinico S. Orsola-Malpighi, Bologna, Italia (CN, PC, SF);Clinica Ematologica, Dip. di Ricerca Clinica e Morfologica, Università di Udine, Italia (FP, SB, RF); Istituto di Medicina Nucleare, Ospedale S. Maria della Misericordia, Udine, Italia (EE, OG); Istituto di Radiologia, Policlinico S. Orsola-Malpighi, Bologna, Italia (ES)

Correspondence: Michele Cavo, M.D., Istituto di Ematologia ed Oncologia Medica "Seràgnoli", Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti, 9 40138 Bologna, Italy. E-mail: mcavo{at}med.unibo.it

TOP ABSTRACT Design and Methods Results Discussion References

 
Background and Objectives: Bone lesions in multiple myeloma (MM) have been traditionally detected by whole body X-ray (WBXR) survey although magnetic resonance imaging (MRI) has become the gold standard for detecting MM involvement of the spine and pelvis. The aim of this study was to compare a new technique, positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) integrated with computed tomography (18F-FDG PET-CT), with MRI and WBXR for baseline assessment of bone disease in MM.

Design and Methods: We prospectively compared 18F-FDG PET-CT, MRI of the spine-pelvis and WBXR for baseline assessment of bone disease in a series of 46 patients with newly diagnosed MM. In 23 patients who received up front autologous transplantation, we also compared post-treatment PET-CT scans with MR images of the spine and pelvis.

Results: Overall, PET-CT was superior to planar radiographs in 46% of patients, including 19% with negative WBXR. In 30% of patients, PET-CT scans of the spine and pelvis failed to show abnormal findings in areas in which MRI revealed an abnormal pattern of bone marrow involvement, more frequently of diffuse type. In contrast, in 35% of patients PET-CT enabled the detection of myelomatous lesions in areas which were out of the field of view of MRI. By combining MRI of the spine-pelvis and 18F-FDG PET-CT, the ability to detect sites of active MM, both medullary and extramedullary, was as high as 92%. Following transplantation, 15 patients had negative PET-CT scans (including 13 with a very good partial response or at least near complete response), but only 8 had normal MRI.

Interpretation and Conclusions: MRI of the spine and pelvis still remains the gold standard imaging technique for the detection of bone marrow involvement in MM. 18F-FDG PET-CT provides additional and valuable information for the assessment of myeloma bone disease in areas not covered by MRI.

Key words: ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging, whole-body planar radiographs, bone disease, multiple myeloma.

Multiple myeloma (MM) is a malignant plasma cell disorder which characteristically involves the skeleton as the result of a cytokine/chemokine-mediated imbalance between increased osteoclast activity and reduced osteoblast function. Clinically, patients suffer from bone pain due to osteoporosis and/or lytic bone lesions, are at increased risk of pathological fractures and may develop neurological complications or hypercalcemia.^1–5 For almost four decades, bone lesions in MM have traditionally been detected by means of whole body X-ray (WBXR) survey.⁶ However, alternative techniques have been recently proposed, including magnetic resonance imaging (MRI),^7,8 bone scintigraphy with technetium-99m (99mTc) sestamibi⁹ and positron emission tomography (PET) with the positron-emitting radionuclide 18F-fluorodeoxyglucose (18F-FDG).^10,11 18F-FDG PET is a newer, non-invasive, total body imaging method which has been widely used to detect malignant cells and monitor treatment response in patients with solid tumors and lymphomas.^10,11 Preliminary observations suggest that FDG PET may also be useful in MM for detecting both medullary and extramedullary disease. ^12–15 However, whether this newer imaging method may replace standard techniques in the staging work-up of newly diagnosed MM is still an unresolved issue which needs to be carefully addressed in the context of well-designed studies. The aim of the present study was a prospective comparison of 18FFDG PET integrated with computed tomography (18FDG PET-CT), MRI and WBXR for the assessment of bone involvement in a series of 46 consecutive patients with previously untreated MM.

TOP ABSTRACT Design and Methods Results Discussion References

 
Forty-six patients entered this prospective study which was conducted at two hematology centers (Bologna and Udine) from March 2003 to December 2004. Of these 46 patients, 44 were referred with a diagnosis of MM, which was subsequently confirmed;¹⁶ the last two patients had an initial diagnosis of solitary plasmacytoma of bone, which was subsequently changed to MM based on PET-CT findings. Once the diagnosis of symptomatic MM had been established, all patients were enrolled in the "Bologna 2002" clinical trial and received primary therapy with thalidomide-dexamethasone, as described elsewhere,¹⁷ followed by double autologous transplantation to support two sequential courses of melphalan 200 mg/m². The clinical and hematologic characteristics at presentation of the 46 patients who form the basis of the present study are summarized in Table 1.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 1. Patients’ baseline characteristics.

Assessment of bone involvement prior to the start of therapy was performed in all patients by means of whole-body 18F-FDG PET-CT, MRI of the spine and pelvis and WBXR survey. In all patients, FDG PET-CT was performed within 2 weeks of WBXR and MRI.

Whole-body (including skull, upper limbs and femora) 18F-FDG PET-CT was carried out using standard procedures, as previously described.¹⁵ PET-CT scans were independently and prospectively reviewed by two nuclear medicine physicians who were blinded to the patients’ clinical characteristics at baseline, as well as to the results of the WBXR survey and MR images of the spine and pelvis. Non-physiologic areas of increased 18F-FDG uptake were considered positive for myelomatous bone involvement if the standard uptake volume (SUV) max based on body weight was >2.5 and a lytic bone lesion was recognized on the corresponding CT images. Areas of focal uptake of the tracer, in the absence of a correspondent lytic image on CT, were not considered positive for myelomatous bone involvement. By study design, no needle biopsy was performed in an attempt to confirm the diagnosis of MM histologically.

MRI was performed according to previously published methods;¹⁸ T1-weighted images were repeated after the intravenous injection of gadolinium chelate. MR images were reviewed by two radiologists who were blinded to the WBXR images and PET-CT scans. They independently evaluated the bone marrow infiltration and, on the basis of previously reported criteria, identified the following patterns of bone marrow involvement: normal, focal and diffuse.¹⁸ In the case of focal pattern, the exact number and site of lesions were reported. WBXR survey included plain radiographs of the skull, spine, pelvis, ribs, femora and humeri.

As previously mentioned, another objective of our study was to compare the accuracy of PET-CT with that of MR of the spine and pelvis for the assessment of response to stem-cell-supported high-dose therapy. Response criteria were those proposed by Bladè et al.,¹⁸ with the addition of a near complete response category, as identified by disappearance of M protein on routine electrophoresis, but positive immunofixation. Criteria used for evaluation of MRI following therapy were previously reported;²⁰ in particular, complete response included resolution of marrow abnormality or persistent abnormality without enhancement, whereas a decrease in the amount of marrow abnormality with persistent enhancement were considered a partial response. PETCT was considered negative if every area of increased tracer uptake found at baseline disappeared following autologous transplantation, while it was defined as improved (partial response) if the number of sites of FDG uptake decreased and/or the SUV of the lesions decreased. According to previously published studies,²¹ response was evaluated 3 months after transplantation.

TOP ABSTRACT Design and Methods Results Discussion References

 
Comparison of 18F-FDG PET-CT with WBXR at baseline
Overall, the comparison of accuracy of FDG PET-CT with WBXR for assessment of myeloma bone disease at baseline showed the superiority of PET-CT over planar radiographs in 21/46 patients (46%), of whom nine were negative for bone osteolyses on planar radiographs and 12 had an extent and magnitude of bone involvement significantly underestimated by WBXR in comparison with PET-CT; p<0.000 (Tables 2 and 3). In particular, in a single patient the finding of multiple sites of increased tracer uptake in the skeleton (all of them out of the FOV of MRI) changed the diagnosis from solitary plasmacytoma of bone, as previously established on the basis of plain radiographs and MR scans of the spine and pelvis, to that of MM.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 2. Comparative imagings of 18F-FDG PET-CT, MRI and WBXR at baseline.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 3. Comparison of the accuracy of different imaging methods in the assessment of myelomatous lesions at baseline.

In an additional 21/46 patients (46% of cases) results of both techniques were comparable (Table 2). Notably, all the 9 patients with negative WBXR and PET-CT findings had an abnormal bone marrow pattern on MRI of the spine. Finally, in the last four patients (8%), no areas of increased 18F-FDG uptake were found on PET-CT, whereas WBXR showed small lytic bone lesions of subcentimeter size in the skull. Of note, all these patients showed an abnormal spinal bone marrow pattern on MRI (Table 2). In conclusion, in the whole patient population the sensitivity of 18F-FDG PET-CT for assessment of myeloma bone disease was 92%. The specificity of the hybrid PET-CT technique was directly demonstrated in all the patients by the morphologic appearance of a lytic lesion on the correspondent CT image of each area of increased bone marrow uptake of 18F-FDG.

Comparison of 18F-FDG PET-CT with MRI at baseline
Overall, comparison of the accuracy of MRI and FDG PET-CT for the detection of bone lesions in the spine and pelvis showed concordant findings in 32/46 patients (70%) and discordant results (e.g. negative PET-CT, but positive MRI) in the remaining 30% of cases (14/46, of whom 10 had a diffuse pattern and 4 had a focal pattern of bone marrow involvement on MRI) (Table 2).

Finally, in 16/46 patients (35%), PET-CT scans enabled detection of myelomatous lesions in sites (medullary: 15 patients; extramedullary: 1 patient) which were out of the FOV of MRI, thus contributing to a more careful assessment of myeloma bone disease. It is worthy of note that in the single patient with extramedullary increased tracer uptake in the liver, a biopsy to confirm the diagnosis of MM was not performed for anatomical reasons. Nevertheless, the SUV of tracer uptake was almost comparable to that seen in the skeleton; moreover, complete resolution of 18F-FDG uptake was observed at re-evaluation following autologous transplantation. In addition, in another patient, the finding of multiple sites of FDG uptake out of the FOV of MRI corrected the diagnosis from solitary plasmacytoma of bone, as previously established on the basis of MRI survey, to that of MM.

Comparison of 18F-FDG PET-CT with MRI according to treatment response at 3 months after autologous transplantation
In 23 patients, bone marrow involvement was re-evaluated 3 months after autologous transplantation. PETCT scans and MR images at re-evaluation were compared with those at baseline and both findings were analyzed in relationship to response to high-dose therapy (Table 4). In 15 patients (65%), 18F-FDG PET-CT scans at re-evaluation were negative and in 12 of these patients a 90% decrease in M protein concentration was documented. Of these 15 patients, eight had a normal MR bone marrow pattern of the spine and pelvis, whereas in the remaining seven patients MRI was either unchanged or showed a reduced number of lesions. In the remaining eight patients, 18F-FDG PET-CT was considered to be improved, according to the criteria above mentioned. Of these eight patients, six had an unmodified MRI, whereas two patients had an improvement in the MR pattern.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 4. Post-transplant comparison of PET-CT vs MR imagings and treatment response in 23 patients.

TOP ABSTRACT Design and Methods Results Discussion References

 
Studies aimed at comparing FDG-PET with conventional techniques for the detection of bone disease at the onset of MM have been limited and incomplete, due to the small number of patients analyzed, most frequently in a retrospective fashion, and, more importantly, to the lack of data confirming the diagnosis of MM.^{9,12,13,14,15,22} To the best of our knowledge, the present study is the first designed to prospectively compare 18F-FDG PET-CT, MRI and WBXR in a relatively large series of newly diagnosed MM patients who were homogeneously treated and for whom all correlative data were available in all the cases analyzed. Although preliminary results of this study were previously reported,¹⁵ in the current analysis we nearly doubled the sample size by including another 18 patients, thus improving the accuracy of the results and reporting one of the largest prospective series so far evaluated at diagnosis with three different imaging techniques. In addition, in this series of patients who were homogeneously treated with autologous stem-cell transplantation, we compared the role of PET-CT and MRI of the spine and pelvis in the assessment of treatment response. Furthermore, we also analyzed the results in relationship to the quality of response to autologous transplantation. For this purpose, we used a hybrid system of 18F-FDG PET integrated with CT which allowed exact detection of small and/or slightly active lesions that could not been easily recognized, or differentiated from soft tissue lesions, on the basis of PET alone. In addition, due to the generation of fused images on which each hypermetabolic lesion was concordant with the morphology of a lytic bone lesion on the corresponding CT image, we were able to directly confirm the reliability and specificity of our PET-CT findings in all the patients who were analyzed. Thus, the diagnostic accuracy of PET-CT used in the present study is likely to be superior to that of all other studies of PET alone so far reported in the literature.²³

Overall, skeletal involvement was documented by WBXR in 61% of newly diagnosed MM patients and by PET-CT in 72% of patients (Table 3). By combining these two imaging methods, the ability to detect myelomatous lesions, both medullary and extramedullary, increased up to 80%. In 46% of patients, PET-CT was superior to WBXR in terms of the ability to reveal small bone lesions which, albeit included in the FOV of planar radiographs, were under the spatial resolution limit of the plain film. Notably, in 19% of these patients WBXR failed to detect bone lytic lesions. No false-positive results were documented in any of the patients with PET-CT positive scans. In contrast, false negative PET-CT scans were found in 8% of patients in whom planar radiographs showed subcentimeter lytic lesions of the skull, a finding consistent with the known difficulty of 18F-FDG PET to reveal skull lesions due to the high, physiologic uptake of the tracer in the adjacent brain.¹¹ It is worthy of note that in all these patients MRI revealed an abnormal pattern of bone marrow in the spine and pelvis.

The comparison between PET-CT scans and MR images with respect to the assessment of bone disease in the spine and pelvis showed that the sensitivity of MRI was as high as 92%, whereas increased uptake of 18FFDG was documented in only 59% of patients (Table 3). Careful analysis of 30% of patients with false-negative PET-CT scans and positive MR images, revealed an abnormal, diffuse pattern of the bone marrow in ten out of 14 patients. Thus, MRI of the spine and pelvis was more sensitive and specific than PET-CT, particularly among patients lacking a focal MR bone marrow pattern. On the basis of these results, which resemble those of previously published studies,^22,24 and in the light of the adverse prognostic relevance of an abnormal diffuse MR pattern of the spine,¹⁸ it can be concluded that MRI still remains the gold standard technique for the detection of bone marrow involvement of the spine and pelvis.

Another objective of our analysis was to assess the complementary role of PET-CT for the assessment of whole-body bone disease, particularly in the light of the FOV of MRI which was limited to the spine and pelvis. In 35% of patients, PET-CT allowed the detection of myelomatous lesions which were out of the FOV of MRI, and were thus missed by this technique (Table 2 and 3). By combining MRI of the spine-pelvis and 18FFDG PET-CT, the ability to detect medullary and, albeit occasionally, extramedullary myelomatous lesions increased up to 92%. As a result of this work, only four patients with damage to organs other than the skeleton (e.g. the bone marrow with related anemia or the kidney with related renal failure) were found to have negative whole body PET-CT scans and MR imagings of the spine and pelvis.

Even now, uncertainties still exist concerning the optimal imaging method to be used for the assessment and monitoring of response to therapy in patients with MM. 18F-FDG PET-CT may be of value given that response can be carefully assessed by recording changes in 18FFDG uptake. Preliminary results of our study showed that in 65% of patients PET-CT scans normalized following autologous transplantation and that this finding closely followed the achievement of a marked (e.g 90%) degree of tumor response. In contrast, normalization of MRI was seen in only 35% of patients. However, a 3-month evaluation of post-transplant response, although based on a previously reported analysis of M protein changes,²¹ may not be an adequate period for MRI reassessment.

In conclusion, PET-CT proved to be a technique that can be used in clinical practice for widespread screening of myelomatous lesions, both medullary and extra-medullary, at the onset of MM. MRI was superior to PET-CT in the assessment of bone marrow involvement of the spine and pelvis. On the basis of these results, which need to be confirmed in larger and independent series of patients, 18F-FDG PET-CT and MRI of the spine and pelvis, with eventual addition of plain X ray of the skull, could be proposed as standard methods for the detection of myeloma bone disease in the routine work-up of patients with newly diagnosed MM. More data and longer follow-up are needed for a better definition of the role of 18 F-FDG PET-CT in assessment and monitoring of response to therapy.

 
Funding: this paper was supported by Università di Bologna, Ricerca Fondamentale Orientata (ex 60%) (M.C.); Ministero dell’Università e Ricerca Scientifica (MIUR) progetto FIRB (RBAU012E9A_001) (MC); Fondazione Carisbo, Italy.

Author Contributions

EZ: conception and design of the study, data collection and writing of the paper; CN: performance of PET scans, data collection and interpretation of data; FP: analysis and interpretation of data, revising critically the manuscript; EE: performance of PET scans, data collection and interpretation of data; PC: performance of PET scans, data collection and interpretation of data; OG: performance of PET scans, data collection and interpretation of data; PTo: conception and design of the study, revising critically the manuscript; PTa: acquisition of data, analysis and interpretation; DC: acquisition of data, analysis and interpretation; GP: acquisition of data, analysis and interpretation; MC: collection and acquisition of data; AB: collection and acquisition of data; SV: collection and acquisition of data; RF: critical revision of the manuscript; MB: critical revision of the manuscript; SF: analysis and interpretation of data, critical revision of the manuscript; MC: conception and design of the study, interpretation of data, writing and drafting of the article.

Conflict of Interest

The authors reported no potential conflicts of interest.

Received for publication July 19, 2006. Accepted for publication November 13, 2006.

TOP ABSTRACT Design and Methods Results Discussion References

 

1. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758-69.[CrossRef][Web of Science][Medline]
2. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439- 44.[CrossRef][Web of Science][Medline]
3. Kyle RA, Rajkumar V. Multiple myeloma. N Engl J Med 2004;351:1860-73.[Free Full Text]
4. Sezer O. Myeloma bone disease. Hematology 2005;1:19-24.
5. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 2002;29 Suppl_17: 11-6.[Web of Science][Medline]
6. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-54.[CrossRef][Web of Science][Medline]
7. Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35-9.[CrossRef][Web of Science][Medline]
8. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11-23.[Abstract/Free Full Text]
9. Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium- 99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004;72:32-7.[CrossRef][Web of Science][Medline]
10. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005;23:4577-80.[Free Full Text]
11. Einat Even-Sapir. Imaging of malignant bone involvement by morphologic, scintigraphic and hybrid modalities. J Nucl Med 2005;46:1356-67.[Abstract/Free Full Text]
12. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skel Radiol 2002;31:690-4.[CrossRef][Web of Science][Medline]
13. Schirmeister H, Bommer M, Buck AK, Mller S, Messer P, et al. Initial results in the assessment of multiple myeloma using FDG-PET. Eur J Haematol Med 2002;29:361-6.
14. Durie GM, Waxman AD, D’Agnolo A, Williams CM. Whole body 18FFDG- PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63.[Abstract/Free Full Text]
15. Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525-31.[CrossRef][Web of Science][Medline]
16. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma. Br J Haematol 2001;121:749- 57.
17. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.[Abstract/Free Full Text]
18. Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992;185:833-40.[Abstract/Free Full Text]
19. Bladè J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.[CrossRef][Web of Science][Medline]
20. Moulopolous LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiol 1994;193:441-6.
21. Attal M, Harousseau Jl, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.[Abstract/Free Full Text]
22. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Radiol 2005;184:1199-204.[Abstract/Free Full Text]
23. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006;79:32-6.[Abstract/Free Full Text]
24. Baur A, Stäbler A, Nagel A, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging of Durie and Salmon. Cancer 2002;95:1334-45.[CrossRef][Web of Science][Medline]

This article has been cited by other articles:

				C. J. Hanrahan, C. R. Christensen, and J. R. Crim Current Concepts in the Evaluation of Multiple Myeloma with MR Imaging and FDG PET/CT RadioGraphics, January 1, 2010; 30(1): 127 - 142. [Abstract] [Full Text] [PDF]

				D. Ennishi, Y. Maeda, M. Niiya, K. Shinagawa, and M. Tanimoto Incidental Detection of Acute Lymphoblastic Leukemia on [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 20, 2009; 27(36): e269 - e270. [Full Text] [PDF]

				M.-A. Dimopoulos, L. A. Moulopoulos, and E. Terpos A new pet for myeloma Blood, September 3, 2009; 114(10): 2007 - 2008. [Abstract] [Full Text] [PDF]

				M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood, May 7, 2009; 113(19): 4497 - 4504. [Abstract] [Full Text] [PDF]

				C. P. Shortt, T. G. Gleeson, K. A. Breen, J. McHugh, M. J. O'Connell, P. J. O'Gorman, and S. J. Eustace Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Disease Activity Am. J. Roentgenol., April 1, 2009; 192(4): 980 - 986. [Abstract] [Full Text] [PDF]

				J. F. San-Miguel and M.-V. Mateos How to treat a newly diagnosed young patient with multiple myeloma Hematology, January 1, 2009; 2009(1): 555 - 565. [Abstract] [Full Text] [PDF]

				B. Paiva, M.-B. Vidriales, J. Cervero, G. Mateo, J. J. Perez, M. A. Montalban, A. Sureda, L. Montejano, N. C. Gutierrez, A. G. de Coca, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Blood, November 15, 2008; 112(10): 4017 - 4023. [Abstract] [Full Text] [PDF]

				P.-Y. Salaun, T. Gastinne, E. Frampas, C. Bodet-Milin, P. Moreau, and F. Bodere-Kraeber FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma Haematologica, August 1, 2008; 93(8): 1269 - 1271. [Full Text] [PDF]

				R. Fonti, B. Salvatore, M. Quarantelli, C. Sirignano, S. Segreto, F. Petruzziello, L. Catalano, R. Liuzzi, B. Rotoli, S. Del Vecchio, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma J. Nucl. Med., February 1, 2008; 49(2): 195 - 200. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zamagni, E. Articles by Cavo, M. Search for Related Content PubMed PubMed Citation Articles by Zamagni, E. Articles by Cavo, M.